e-learning
resources
Milan 2017
Sunday, 10.09.2017
Rare diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?
E. Ugur Chousein (ISTANBUL, Turkey)
Source:
International Congress 2017 – Rare diseases
Session:
Rare diseases
Session type:
Poster Discussion
Number:
1519
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Ugur Chousein (ISTANBUL, Turkey). The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?. 1519
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Pulmonary sarcoidosis
Definition and history of sarcoidosis
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Elevated circulating concentrations of adiponectin in sarcoidosis – a new marker of disease?
Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis
Year: 2006
Is there any clinical application for determining the serum cytokines profile in sarcoid patients?
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
Serum C-reactive protein concentrations in patients with sarcoidosis: can be taken this simple test as an activation marker in sarcoidosis?
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004
Serum biomarkers in SSc-ILD: association with presence, severity and prognosis
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
Visfatin as a possible serum biomarker in COPD
Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases
Year: 2019
The serum YKL-40 is a useful biomarker for asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Circulating total leptin as a diagnostic and prognostic biomarker in sepsis
Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Year: 2019
Serum amyloid A as a potential biomarker of sarcoidosis
Source: Annual Congress 2011 - Lung development and neoplasia
Year: 2011
Sarcoidosis: serum and imaging biomarkers
Source: Eur Respir Monogr 2022; 96: 107-121
Year: 2022
Human chitotriosidase analysis: a reliable biomarker of sarcoidosis severity
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017
Is YKL-40 a prognostic marker in sarcoidosis?
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Serum KL-6 and SP-D as useful clinical indicators of interstitial changes and pulmonary functional abnormality in patients with Sjogren's syndrome
Source: Eur Respir J 2001; 18: Suppl. 33, 367s
Year: 2001
Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
KL-6 is a useful serum biomarker for early detection of interstitial lung disease
Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Year: 2012
Serum markers of acute sarcoidosis.
Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases
Year: 2020
The diagnostic value of serum soluble CD 14 and IL-10 levels in newly diagnosed pulmonary tuberculosis patients and the relationship with disease extensity
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay.
Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia
Year: 2019
The effect of exercise on serum amyloid a levels in patients with sarcoidosis: A preliminary report
Source: International Congress 2015 – Sarcoidosis: pathogenesis
Year: 2015
Serum CC16 is a potential predictor for IPF diagnosis and prognosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept